



MODERN EPIDEMIOLOGICAL FEATURES OF MEASLES (LITERATURE REVIEW)

Matnazarova G. S.¹,

Tirkashev O. S.²,

Saidkasimova N. S.¹,

Abdukaxarova M. F.¹

1-Tashkent Medical Academy

2-Samarkand State Medical University

Abstract

The entire world health organization (WHO) according to measles disease is one of the main reasons that brought children to die. 140 thousand died from measles in the world qishi the year 2018, 10 million people suffering from this disease. If known, noted, the main part of his measles unvaccinated against the disease died from the disease made up of children under the age of five.

Keywords: measles, disease, epidemic.

Introduction

According to world health organization data, the present-day world in their position with the incidence of measles every year 60 million. the population consists of only 3 million of them. the condition of the dead is observed between early-age children [WHO, Svirkun O.V., 2014].

Immunoprophylaxis events among those working in the field of health also plays an important role in the country today. Immunoprophylaxis which alarmed the origin and spread of infectious diseases is one of the most effective measures to prevent. According to the World Health Organization, according to the vaccine every year as a result of diphtheria, pertussis, tetanus, will save millions of human lives from infectious diseases such as measles 2.3 of different ages. In the event of this process is the most effective method to maintain the health of the church [5,6].

The main purpose of the vaccine led with special tool immunoprophylaxis complete loss and infections, stipulate that reduce the incidence of death from infectious diseases. Today diphtheria, pertussis, tetanus, measles, rubella, poliomyelitis, tuberculosis, epidemic parotit, viral hepatitis B, rotavirus and preventive vaccinations against infections and when to vp pnevmokokli are included in the national immunization calendar. So basically the new-born baby from the start to cover the mass vaccination of all children under the age of 16 is taken.





World health organization (WHO) according to reference more than 364 thousand in the first six months of the year 2019 in 182 countries, measles disease was recorded. By the end of the year 2019, this figure grow dramatically 869770 person in the world is observed in this disease. 207500 students that the patient died. As a result, death index increased to 50 percent since the year 2016 [96, 98].

The polio virus in 2002 provoke the territory of the republic of uzbekistan received the certificate on the case completely. Also difteriya disease prevention, and the loss of years 2018-2020 qizilcha to achieve measles, viral hepatitis B disease, GI (gemofil infection), and the prevention of rotavirus infection and to reduce pnevmokokk, tuberculosis form the bulk of the virus called papillomavirus finish and the man on the prevention of diseases which are significant work is being conducted in the country. Despite the fact that measles vaccinaphylaxis has been carried out over the past 30 years, especially among older children, severe clinical forms of measles have been increasing. [2, 13, 25].

In 2018-2019, the epidemiological situation in measles was aggravated. It is noted that this disease has spread in the form of a pandemic in 28 European countries [3, 4, 17]. As a result of the expansion of international relations and tourism of the republic of Uzbekistan the year 2018-2019 increasingly come in some regions of measles cable to the d-8 is called with the incidence of virus strains were observed.

In 1912 , in the year of measles in the united states at the national level, which is known the diseasehas become a ca, so that should give Us a message on all cases of diagnosed medical providers and laboratories are required. So basically in the first decade of the report every year, registered in the u.s. 350 million. the incidence of measles among those associated with the average of 6000 and more in the condition of death is noted. In the period from the year 2018 to the year 2020 around the world, and strengthen the health care system a vaccine against the level of expansion qizamiqqa death by 73% was reduced. In 2012, covering the years 2012-2020 begin implementation of a new global strategic plan to combat measles [1,2,4].

At the end of the year, the 2020 goal of who is to finish in five regions butkul measles. However, the regional measles elimination status would be achieved or able to maintain a level beyond the limit cases of death from measles in recent years and on the whole world is going to grow worried were observed. According to the global initial data, 2019 in the first three months of the year have increased 2 percent compared to the year 2018 section. Measles epidemic as noted, there are a number of countries. Such countries are the Democratic Republic of the Congo, Ethiopia, Georgia, Kazakhstan, Kyrgyzstan, Madagascar, Myanmar, the Philippines, Sudan, Thailand and Ukraine. The sharp increase in the disease in recent months is also common in





the United States, Israel, Thailand and Tunisia, including countries that cover the vaccination against measles among the population [118, 119].

World health organization (make it almost not) and measles in europe has announced that it will fight with qizilcha year 2010. However, despite all the efforts, according to who data, 158 000 people died from measles in 2011. Almost 18 per hour or the day to condition in the condition list is 430. Going beyond the limit cases of the disease in low-income countries, the majority of health among vulnerable children has been noted [35].

In the year 2018 at 7.5 million to 9.5 million in the whole world for the year 2019, total units 47 units registered in the state 34300 condition of measles disease in european countries, the epidemiological situation remains difficult to xanuz. For the year 2019 Ukraine (65 000), Serbian (7035), France (5863), Italy (5352), Greece (8542), in the Russian federation (52504), Georgia (8575) Albania (4413), in romania (16210), in the uk (6019), India (53772), Kyrgyzstan (5234), Kazakhstan (more than 20000) and measles disease is noted in 21 children died from measles in the mode that was taken in among the list of mandatorily. More than 142,000 deaths were reported worldwide, in 140 cases in European countries mainly among children under the age of 5: in Albania, Greece and Georgia - 2 cases, in the Russian Federation and France - 13 cases, in Italy - 7 cases, in Serbia - 14 cases, in Ukraine - 41 cases, in Romania - 22 cases, in Kazakhstan - 21 cases. The complication of the epidemic situation in the above-mentioned States was caused by the refusal of the population to be vaccinated against measles 2 times, low vaccination rates and an increase in their anti-vaccination efforts. The 2020 COVID-19 pandemic spread throughout the world caused scheduled vaccinations to be suspended in 26 of the world's countries, resulting in 94 million. children were not vaccinated, planned and secondary vaccination against measles was performed by 35-70% [66, 99].

World health organization (WHO), up to the present day in the world according to their position with reference to the incidence of measles every year 60 million. the population consists of only 3 million of them. died between the condition of children of early age is observed. Currently on the epidemiological situation in european countries and in the whole world is being destroyed by measles disease remains complicated. One of the recommendations of the who COVID-19 to the pandemic necessary to fight against, however the full implementation of the vaccination process led and systematic way death cases of infectious diseases.

Immunoprofilaxis - is the most important factor in the prevention of the onset of the disease. The origin of infectious disease and prevent complications. Just one disease





from the vaccine can be 100 thousand. Vaccination against measles disease in the whole world since the year 2000 on the death of 84% was reduced to percent.

Measles infection is the most common on earth. It occurs in all seasons of the year, autumn-winter and spring during the months of the disease increased, 95 to 96% kontagioz. The source of the disease - the patient people. Kataral of the disease in the period of the 1st day of the period to overflow rash and catching up on a high, 3-day infectious properties will decrease, on the 4th day, the patient is safe. The disease is air-drop way through contracting.

Immunity from mother to child 6 months after birth because of the passage of children with congenital qizimi q kasallanmaydi. Saved lifelong immunity after the disease occurs. Re-is not observed in the incidence of conditions.

Among the cases of death recorded on measles disease in the usa in the years 1985-1992 only 0.2% was observed in all cases. The majority of those who reached the age of five died from the infection.

In developed countries the mortality rate is lower, for example the uk and Uelsda from 2007 to 2017. life and death situation 10000 two of the three have been recorded. None of the three children in every 1000 people in the united states will die from one (and 0.1-0.2%). Death among the population nourished and fed at a high level to have adequate medical care to 10% of it. Died due to measles in the year 2000 to 2012 the number of less than 78 percent, increased the level of immunizasiya among member states of the united nations [35].

The last century has 50 years of the death of their position as a result of improvements in medical care will be reduced, but in the end of the 1960s prior to the commencement of the disease the vaccine is subject to chekinmadi with the incidence of back. In 1980, measles, mumps and rubella (MMR) wide to get coverage with the vaccine achieved.

2013-2014 year in 30 european countries, almost 10 000 units and their position recorded was. Most cases are unvaccinated individuals, more than 90% more than Germany, Italy, Netherlands, Romania and Great Britain occurred have. In the year 2018, according to preliminary data, in the region increased 3-fold have been recorded cases in the country reached 82 ha 596 47, 72 death was recorded. 90 thousand in the first 6 months of the year in Europe 2019 condition that I gave away.

Common disease in America has announced that as a result of end the year in 2016. However, 2017, 2018, 2019 and 2020 in this region, the incidence condition is detected again in the years [108].

Measles disease in the united states in the 1960 s until the vaccine works out to approximately 3000 million people qo'yigunga cover. Common with the vaccine by





1980, this condition figure 13 million, 1 million units by the year 2000 condition while they come down.

Before the vaccine every three years to four million in the united states, the incidence of the condition happened. Measles of the United States of America in the year 2000 from the state was declared to be rotary disease from 2001 to 2011, ta 911 until the condition is noted. The origin and the occasional measles continue to spread, but because of the circumstances that brought abroad, more than half of them become infected and the infected unvaccinated u.s. residents abroad and after returning to the usa to others is the result of [105, 106].

In 2014, two unvaccinated men diagnosed with asymptomatic measles in Ohio returned to the United States from missionary work in the Philippines. Their return to a community with low vaccination rates led to an epidemic that covered a total of 383 cases across nine provinces. Of the 383 cases, 340 (89%) occurred in unvaccinated individuals.

References

1. Agafonova A.S. Otnoshenie studentov meditsinskogo VUZ a k vaksinoprofilaktike protiv kori //Forcipe. 2020. T. 3. № S. S. 580-581.
2. Aydiraliev Ch. K. Programma eliminatsii kori i krasnuxi i profilaktiki vrojdennoy krasnushnoy infektsii v Evropeyskom regione VOZ // PF. 2009. №2.
3. Binyatova A.S., Misa E.D., CHertova N.V., Volkova R.A., Sarkisyan K.A., Ilyasova T.N., Yunasova T.N., Movsesyans A.A., Merkulov V.A. Ispolzovanie naborov reagentov dlya OT-PSR v realnom vremeni dlya otsenki podlinnosti vaksin protiv kori, parotita i krasnuxi // BIO preparati. Profilaktika, diagnostika, lechenie. 2018. №4.
4. Gayderova L. A., Yunasova T. N., Shitikova O. Yu., Popov V. F., Ignatev G. M., Gorbunov M. A. Postregistratsionnaya otsenka otechestvennix i zarubejnix vaksin dlya profilaktiki kori, epidemicheskogo parotita i krasnuxi // BIOpreparati. Profilaktika, diagnostika, lechenie. 2013. №1 (45).
5. Galina N.P., Mindlina A.Ya., Polibin R.V. Analiz organizatsii privivok detskogo i vzroslogo naseleniya RF protiv difterii, stolbnyaka, kori i virusnogo gepatita V//Infeksiya i immunitet. 2019. T. 9. № 5-6. S. 779-786.
6. Eremushkina Ya. M., Vdovina E. T., Kotiv S. I., Kuskova T. K. Algoritm diagnostiki kori v slojnoj epidemicheskoy situatsii. Analiz klinicheskix dannix. // Infektsionnie bolezni. 2015. № 4. S. 76–82.
7. <https://news.un.org/ru/story/2019/04/1353931>



8. Kitarova G.S., Suvanbekov A.A., Vasikova S.G., Kondrateva E.I. Aktivnaya immunizatsiya protiv kori i ee vliyanie na epidemicheskii protsess v Kirgizskoy respublike //Zdravooxranenie Kirgizstana. 2011. № 2. S. 51-54.
9. Kor. Informatsionniy byulleten VOZ. 2019. Novie dannie epidemiologicheskogo nadzora za korYu za 2019 g. <https://www.who.int/immunization/newsroom/measles-data-2019/ru/>
10. Kor. Osnovnie fakti. VOZ. <https://www.who.int/ru/news-room/fact-sheets/detail/measles> Dostup 24.01.2019 <https://www.who.int/ru/news-room/fact-sheets/detail/measles> Accessed 24.01.2019]
11. Kostinov Mixail Petrovich. Immunoprofilaktika kori s primeneniem kombinirovannix vaksin //Epidemiologiya i vaksinoprofilaktika. 2020. T. 19. № 4. S. 57-62.
12. Krasnova E.M., Sanjapova G.S. Immunoprofilaktika kak effektivniy sposob borbi s koryu //Infeksiya i immunitet. 2017. № 5. S. 593.
13. Litkina I.N., Mixeeva I.V. Unifikatsiya sistemi upravleniya epidemicheskimi protsessami kori, epidemicheskogo parotita i krasnuxi//Epidemiologiya i vaksinoprofilaktika. 2011. № 1 (56). S. 9-16.
14. Lvova I.I., Minaeva N.V., FeldblYum I.V. Sovremennaya texnologiya povisheniya effektivnosti aktivnoy immunizatsii detey s sindromom narusheniya protivoinfeksionnoy zashiti //Meditsinskiy almanax. 2012. № 3 (22). S. 141-144.
15. Mamaeva T. A., Jeleznova N. V., Naumova M. A. i dr. Algoritm laboratornogo podtverjdeniya i differentsialnoy diagnostiki korevoy infektsii v period eliminatsii kori v Rossiyskoy Federatsii // Infeksiya i immunitet. 2015. № 1. S. 55–62.
16. Maxmudova D.I., Tursunova D.A., Safaeva K.S. Dostizheniya, problemi i puti obespecheniya svoevremennosti oxvata vaksinatsey v Respublike Uzbekistan (RUz) // Vserossiyskaya nauchno-prakticheskaya konferentsiya s mejdunarodnim uchastiem (Moskva, 17-18 oktyabrya 2019 g) – S. 27
17. Moiseeva A.V. Vliyanie immunoprofilaktiki na epidemicheskii protsess kori //Zdorove rebenka. 2010. № 3 (24). S. 89-92.
18. NikitYuk N.F., Yurevich M.A. Immunoprofilaktika kori v organizovannix kollektivax na etape eliminatsii korevoy infektsii //Biopreparati. Profilaktika, diagnostika, lechenie. 2011. № 3 (43). 42-44.
19. Niyazalieva M.S., Toygombaeva V.S., Asikbekova B.SH., Orozakunova N.O. Sovremennaya epidemiologicheskaya situatsiya vaksinoupravlyaemix infektsiy sredi jiteley g. Bishkek //Vestnik Avitsenni. 2016. № 1 (66). S. 85-90.



20. Niyazalieva M.S., Toygombaeva V.S. EvolYusiya epidemicheskogo protsessa kori v Kirgizskoy respublike //Vestnik Kirgizsko-Rossiyskogo Slavyanskogo universiteta. 2015. T. 15. № 7. S. 117-120.
21. Orlova O.G., Ermolenko O.V, Ribalchenko E.I. «Morbillivirus - virus kori. Obshaya xarakteristika i diagnostika infektsii» - uchebno-metodicheskoe posobie. Sankt-Peterburg. 2014. 25 s.
22. O situatsii s zaboлеваemostYu koryu v Rossii i zarubejnih stranax 11.02.2019 g. URL: http://www.rospotrebnadzor.ru/about/info/news/news_details.php
23. Osobennosti diagnostiki i profilaktiki kori na sovremennom etape <https://www.lvrach.ru/2019/11/15437431> SanPin №0239-07, Tashkent – 2015, s. 27.
24. Paxomov Dmitriy Vladimirovich Obosnovanniy put bezopasnoy vaksinatcii protiv kori, krasnuxi i epidemicheskogo parotita detey, rojdennix VICH-infitsirovannimi materyami, i VICH-infitsirovannix detey // Infektsionnie bolezni: Novosti. Mneniya. Obuchenie. 2018. №2 (25).
25. Pozdnyakov A.A., Chernyavskaya O.P. Proyavleniya epidemicheskogo protsessa kori i krasnuxi na sovremennom etape //Epidemiologiya i vaksinoprofilaktika. 2018. T. 17. № 5 (102). S. 45-53.
26. Popov E.A., Zlakomanova O.N., Moskvicheva M.G. Immunologicheskaya effektivnost vaksinatcii protiv kori u detey, poseshaYushix organizovannie detskie kollektivi //Rossiyskiy immunologicheskij jurnal. 2014. T. 8(17). № 3. S. 920-922.
27. Saidaliev S.S. Spetsificheskaya immunoprofilaktika infektsionnix zabolevaniy respublike Uzbekistan//Meditsinskie novosti. 2017. № 12. S. 41-43.
28. Saidaliev S.S., Mamatkulov B. Immunizatsii naseleniya v respublike Uzbekistan //V sbornike: Sovremennaya meditsina: novie podxodi i aktualnie issledovaniya. Sbornik statey po materialam V mejdunarodnoy nauchno-prakticheskoy konferentsii. 2017. S. 115-120.
29. Sovremennaya immunoprofilaktika: vizovi, vozmojnosti, perspektivi: Vserossiyskaya nauchno-prakticheskaya konferentsiya s mejdunarodnim uchastiem (Moskva, 17-18 oktyabrya 2019 g) / pod red. Akimkina V.G., - M., FBUN SNII Epidemiologii Rospotrebnadzora, 2019. S. 66.
30. Soloveva Irina Leonidovna, Lejen Elena Mixaylovna, Kuselman Aleksey Isaevich, Kostinov Mixail Petrovich, Mukanova Dinara Serikovna, Krasheninnikova Ekaterina Yurevna Vaksinatciya chasto boleYushix detey otechestvennoy parotitno-korevoy vaksinoy // Ulyanovskiy mediko-biologicheskij jurnal. 2013. №2.
31. Toptigina Anna Pavlovna, Aziatseva V. V., Savkin I. A., Kislitsin A. A., Semikina E. L., Grebennikov D. S., Aleshkin A. V., Sulimov A. V., Sulimov V. B., Bocharov G. A. Prognozirovaniye spetsificheskogo gumoralnogo immunnogo otveta na osnovanii



- isxodnix parametrov immunnogo statusa detey, privitix protiv kori, krasnuxi i epidemicheskogo parotita // Immunologiya. 2015. №1.
32. Tolegenova A.M., Alekesheva L.J., Smagul M.A. Epidemiologicheskaya xarakteristika korevoy infektsii po dannim retrospektivnogo epidemiologicheskogo analiza // Vestnik Kazaxskogo natsionalnogo meditsinskogo universiteta. 2020. № 1. S. 393-396.
33. Trete soveshanie Evropeyskoy regionalnoy komissii po verifikatsii eliminatsii kori i krasnuxi (RKV) 10-12 noyabrya 2014 goda – Kopengagen, Daniya.
34. Xarit Susanna Mixaylovna, Ruleva A.A., Goleva O.V., Kalinogorskaya O.S., Apryatina V.A. Rezultati issledovaniya urovney spetsificheskix antitel na sochetannoe vvedenie vaksin protiv grippa, kori, krasnuxi i parotita i ADS-M u detey s xronicheskimi somaticheskimi zabolevaniyami // Detskie infektsii. 2014. №3.
35. Xolmatova YO., Sobirjonova M., Jo'raeva M. Dostignutie uspexi v immunoprofilaktike respubliki Uzbekistan // MIROVAYA NAUKA. - 2022. - №1.- S. 554-558.
36. Shamsutdinova Olga Anatolevna. Jivie attenuirovannie vaksini dlya immunoprofilaktiki // Infeksiya i immunitet. 2017. №2. Atkinson W (2011). *Epidemiology and Prevention of Vaccine-Preventable Diseases* (12 ed.). Public Health Foundation. pp. 301–23. ISBN 9780983263135. Archived from the original on 7 February 2015. Retrieved 5 February 2015.
37. Awotiwon AA, Oduwole O, Sinha A, Okwundu CI (June 2017). "Zinc supplementation for the treatment of measles in children". *The Cochrane Database of Systematic Reviews*. CDO11177.doi:10.1002/14651858.CDO11177. pub3. PMC 6481361. PMID 28631310.
38. Bartlett, M.S. (1957). "Measles periodicity and community size". *J. R. Stat. Soc. Ser. A* (120): 48–70.
39. Baxby D (July 1997). "The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal mucous membrane By Henry Koplik, M.D. Reproduced from Arch. Paed. 13, 918-922 (1886)". *Reviews in Medical Virology*. (2): 71–74. doi:10.1002/(SICI)1099-1654(199707)7:2<71::AID-RMV185>3.0.CO;2-S . PMID 10398471.
40. Bester, Johan Christiaan (1 December 2016). "Measles and Measles Vaccination". *JAMA Pediatrics*. (12): 1209–1215. doi:10.1001/jamapediatrics.2016.1787. PMID 27695849.
41. Brown, Kevin E.; Rota, Paul A.; Goodson, James L.; Williams, David; Abernathy, Emily; Takeda, Makoto; Mulders, Mick N. (5 July 2019). "Genetic Characterization of Measles and Rubella Viruses Detected Through Global Measles and Rubella





- Elimination Surveillance, 2016–2018". *MMWR. Morbidity and Mortality Weekly Report*. (26): 587–591. doi:10.15585/mmwr.mm6826a3. PMC 6613570. PMID 31269012.
42. Caserta, MT, ed. (September 2013). "Measles". Merck Manual Professional. Merck Sharp & Dohme Corp. Archived from the original on 23 March 2014. Retrieved 23 March 2014.
43. Centers for Disease Control (CDC) (May 1982). "Recommendation of the Immunization Practices Advisory Committee (ACIP). Measles prevention". *MMWR. Morbidity and Mortality Weekly Report*. (17): 217–24, 229–31. PMID 6804783.
44. "CDC Media Statement: Measles cases in the U.S. are highest since measles was eliminated in 2000". *Centers for Disease Control and Prevention (CDC)* (Press release). 26 April 2019.
45. Chen S.S.P. (22 February 2018). Measles (Report). Medscape. Archived from the original on 25 September 2011. Retrieved 13 May 2020.
46. Crum, Frederick S (April 1914). "A Statistical Study of Measles". *American Journal of Public Health*. (4): 289–309. doi:10.2105/AJPH.4.4.289-a. PMC 1286334. PMID 18009016.
47. Di Pietrantonj, Carlo; Rivetti, Alessandro; Marchione, Pasquale; Debalini, Maria Grazia; Demicheli, Vittorio (20 April 2020). Cochrane Acute Respiratory Infections Group (ed.). "Vaccines for measles, mumps, rubella, and varicella in children". *Cochrane Database of Systematic Reviews*. CD004407. doi:10.1002/14651858.CD004407.pub4. PMC 7169657. PMID 32309885.
48. Dimech, Wayne; Mulders, Mick N. (July 2016). "A review of testing used in seroprevalence studies on measles and rubella". *Vaccine*. (35): 4119–4122. doi:10.1016/j.vaccine.2016.06.006. PMID 27340096.
49. Dubé E, Gagnon D, Ouakki M, Bettinger JA Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. // PLoS One. 2016 Jun 3; 11(6): e 0156118.
50. Ellison J.B. (February 1931). "Pneumonia in Measles". *Archives of Disease in Childhood*. 6 (31): 37–52. doi:10.1136/adc.6.31.37. PMC 1975146. PMID 21031836. 01.05.2021. Measles -Wikipedia. <https://en.m.wikipedia.org/wiki/Measles> 23/32
51. "European Region loses ground in effort to eliminate measles". *World Health Organization (WHO)* (Press release). 29 August 2019. Archived from the original on 14 April 2020. Retrieved 31 August 2019.
52. Fisher D.L, Defres S., Solomon T. (March 2015). "Measles-induced encephalitis". *QJM*. (3): 177–82. doi:10.1093/qjmed/hcu113. PMID 24865261.



53. "First Measles Death in US Since 2003 Highlights the Unknown Vulnerables – Phenomena: Germination". 2 July 2015. Retrieved 13 May 2020.
54. "Frequently Asked Questions about Measles". Washington State Department of Health. Retrieved 10 February 2019. "[Vitamin A] cannot prevent or cure the measles"
55. Friedman M, Hadari I, Goldstein V, Sarov I (October 1983). "Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection". *Israel Journal of Medical Sciences*. (10):881–4. PMID 6662670.
56. Gardiner, W. T. (2007). "Otitis Media in Measles". *The Journal of Laryngology & Otology*.: 614–17. doi:10.1017/S0022215100026712.
57. "Global goal to reduce measles deaths in children surpassed" (Press release). UNICEF. 2007. Archived from the original on 4 February 2015. Retrieved 11 March 2015.
58. "Global Measles Outbreaks". *cdc.gov*. 17 August 2020. Retrieved 4 September 2020.
59. Greenwood, Kathryn P.; Hafiz, Radwan; Ware, Robert S.; Lambert, Stephen B. (17 May 2016). "A systematic review of human-to-human transmission of measles vaccine virus". *Vaccine*. (23):2531–2536. doi:10.1016/j.vaccine.2016.03.092. ISSN 1873-2518. PMID 27083423.
60. GRIFFIN, ASHLEY HAGEN (18 May 2019). "Measles and Immune Amnesia". *asm.org*. American Society for Microbiology. Archived from the original on 18 January 2020. Retrieved 18 January 2020.
61. Guglielmi, Giorgia (31 October 2019). "Measles erases immune 'memory' for other diseases". *Nature*. doi:10.1038/d41586-019-03324-7. PMID 33122832. Retrieved 3 November 2019.
62. Hamborsky, Jennifer; Kroger, Andrew; Wolfe, Charles, eds. (2015). *Epidemiology and prevention of vaccine-preventable diseases* (13th ed.). [Atlanta, GA]. p. 211. ISBN 978-0-9904491-1-9. OCLC 915815516.
63. Hayman DTS. Measles vaccination in an increasingly immunized and developed world. //Hum Vaccin Immunother. 2019;15(1):28-33
64. Howard J, Goldschmidt D (24 April 2019). "US measles outbreak is largest since disease was declared eliminated in 2000". *CNN*. Retrieved 24 April 2019.
65. Joint News Release (5 December 2019). "More than 140,000 die from measles as cases surge worldwide".who.int. Retrieved 4 September 2020.
66. Kabra SK, Lodha R (August 2013). "Antibiotics for preventing complications in children with measles". *The Cochrane Database of Systematic Reviews*. CD001477. doi:10.1002/14651858.CD001477.pub4. PMC 7055587. PMID 23943263.





67. Leuridan E, Sabbe M, Van Damme P (September 2012). "Measles outbreak in Europe: susceptibility of infants too young to be immunized". 5905–13. doi:10.1016/j.vaccine.2012.07.035. PMID 22841972.
68. Ludlow M, McQuaid S, Milner D, de Swart RL, Duprex WP (January 2015). "Pathological consequences of systemic measles virus infection". *The Journal of Pathology*. 253–65. doi:10.1002/path.4457. PMID 25294240.
69. McLean H.Q., Fiebelkorn A.P., Temte J.L., Wallace G.S. (June 2013). "Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). *MMWR. Recommendations and Reports*. (RR-04): 2, 19. PMID 23760231. Archived from the original (PDF) on 13 April 2020.
70. "Measles Cases and Outbreaks". *Centers for Disease Control and Prevention (CDC)*. 6 January 2020. Archived from the original on 1 November 2019. Retrieved 6 January 2020. *This article incorporates text from this source, which is in the public domain*. 01.05.2021 Measles - Wikipedia <https://en.m.wikipedia.org/wiki/Measles> 28/32
71. "Measles cases spike globally due to gaps in vaccination coverage". *World Health Organization (WHO)*. 29 November 2018. Retrieved 21 December 2018.
72. "Measles". *Centers for Disease Control and Prevention (CDC)*. Archived from the original on 23 October 2016. Retrieved 22 October 2016.
73. "Measles". *Centers for Disease Control and Prevention (CDC)*. 2 April 2018. Retrieved 8 May 2018. 01.05.2021 Measles - Wikipedia <https://en.m.wikipedia.org/wiki/Measles> 24/32.
74. "Measles". *Centers for Disease Control and Prevention (CDC)*. 2 April 2018. Retrieved 6 May 2018.
75. "Measles Data and Statistics" (PDF). Retrieved 15 August 2019.
76. "Measles – European Region". *World Health Organization (WHO)*. Retrieved 8 May 2019.
77. "Measles fact sheet". *World Health Organization (WHO)*. Retrieved 20 May 2019. References 01.05.2021 Measles - Wikipedia <https://en.m.wikipedia.org/wiki/Measles> 21/32.
78. "Measles Frequently Asked Questions about Measles in U.S". *Centers for Disease Control and Prevention (CDC)*. 28 August 2018.
79. "Measles in Europe: record number of both sick and immunized" (Press release). World Health Organization (WHO). 7 February 2019. Retrieved 27 March 2019.



80. "Measles". Merck Manuals Professional Edition. January 2018. Retrieved 6 May 2018.
81. "Measles notifications and deaths in England and Wales: 1940 to 2017". GOV.UK. Retrieved 1 October 2019.
82. "Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP) Archived 2012-05-15 at the Wayback Machine". Centers for Disease Control and Prevention (CDC).
83. "Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP)". *cdc.gov*. 29 December 1989. Retrieved 13 November 2020.
84. "Measles: Questions and Answers" (PDF). Immunization Action Coalition. Archived from the original on 24 January 2013.
85. "Measles (Red Measles, Rubeola)". *Dept of Health, Saskatchewan*. Archived from the original on 10 February 2015. Retrieved 10 February 2015.
86. "Measles (Rubeola) Signs and Symptoms". Centers for Disease Control and Prevention (CDC). 3 November 2014. Archived from the original on 2 February 2015. Retrieved 5 February 2015
87. "Measles spreads again in the Americas". *MercoPress*. 28 March 2018. Retrieved 4 July 2018.
88. "Measles Surveillance Data". World Health Organization (WHO). 17 March 2015. Archived from the original on 3 July 2015.
89. "Measles-United States, 2005". Centers for Disease Control and Prevention (CDC). 22 December 2006. Archived from the original on 13 March 2015. Retrieved 30 March 2015.
90. "Measles". World Health Organization (WHO). 23 July 2013. Archived from the original on 14 August 2013.
91. "More than 140,000 die from measles as cases surge worldwide". *World Health Organization (WHO)* (Press release). 5 December 2019. Retrieved 12 December 2019.
92. Moss W.J., Griffin D.E. (January 2012). "Measles". *Lancet*. (9811): 153–64. doi:10.1016/S0140-6736(10)62352-5. PMID 21855993. S2CID 208794084.
93. "New measles surveillance data for 2019" (Press release). World Health Organization (WHO). 15 April 2019. Retrieved 4 June 2019.
94. "Number of Reported Measles Cases with onset date from Nov 2014 to Apr 2015 (6M period)" (PDF). World Health Organization (WHO). Archived from the original on 3 July 2015.





95. Olugbade OT, Adeyemi AS, Adeoti AH, Ilesanmi OS, Gidado SO, Waziri NE, Aworh MK. Measles outbreaks and Supplemental Immunization Activities (SIAs): the Gwagwalada experience, Abuja 2015. // *Pan Afr Med J.* 2019 Jan 24;32
96. Patel, Minal K.; Goodson, James L.; Alexander, James P.; Kretsinger, Katrina; Sodha, Samir V.; Steulet, Claudia; Gacic-Dobo, Marta; Rota, Paul A.; McFarland, Jeffrey; Menning, Lisa; Mulders, Mick N. (13 November 2020). "Progress Toward Regional Measles Elimination — Worldwide, 2000–2019". *MMWR. Morbidity and Mortality Weekly Report.* (45): 1700–1705. doi:10.15585/mmwr.mm6945a6. ISSN 0149-2195. PMC 7660667. PMID 33180759.
97. "Pinkbook Measles Epidemiology of Vaccine Preventable Diseases". *Centers for Disease Control and Prevention (CDC)*. 15 November 2016. Retrieved 6 May 2018.
98. "Region of the Americas is declared free of measles". *Pan American Health Organization*. 29 September 2016. Archived from the original on 30 September 2016. Retrieved 30 September 2016.
99. "Reported measles cases and incidence rates by WHO Member States 2013, 2014 as of 11 February 2015" (PDF). World Health Organization (WHO). 7 April 2014. Archived from the original on 3 July 2015.
100. Rezaie SR. "Measles: The Sequel". *Emergency Physicians Monthly*. Retrieved 7 June 2019.
101. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL (July 2016). "Measles". *Nature Reviews. Disease Primers.* 2: 16049. doi:10.1038/nrdp.2016.49. PMID 27411684.
102. Sabella C (March 2010). "Measles: not just a childhood rash". *Cleveland Clinic Journal of Medicine.* 77 (3): 207–13. doi:10.3949/ccjm.77a.09123. PMID 20200172. S2CID 4743168.
103. Semba RD, Bloem MW (March 2004). "Measles blindness". *Survey of Ophthalmology.* 49 (2): 243–55. doi:10.1016/j.survophthal.2003.12.005. PMID 14998696.
104. Steichen O, Dautheville S (March 2009). "Koplik spots in early measles". *CMAJ.* 180 (5): 583. doi:10.1503/cmaj.080724. PMC 2645467. PMID 19255085.
105. "Surveillance Manual | Measles | Vaccine Preventable Diseases | CDC". *www.cdc.gov*. 23 May 2019. Retrieved 25 November 2019.
106. "Symptoms of measles". National Health Service (NHS). 26 January 2010. Archived from the original on 31 January 2011.
107. "U.S. measles cases surge nearly 20 percent in early April, CDC says". Retrieved 16 April 2019.





108. Wong LP, Wong PF, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. // *Hum Vaccin Immunother.* 2020 Jul 2;16(7):1511-1520.
109. Wong LP, Wong PF, Megat Hashim MMAA, Han L, Lin Y, Hu Z, Zhao Q, Zimet GD. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. // *Hum Vaccin Immunother.* 2020 Jul 2;16(7):1611-1622.
110. World Health Organization (April 2017). "Measles vaccines: WHO position paper – April 2017". *Weekly Epidemiological Record.*: 205–27. hdl:10665/255377. PMID 28459148.
111. World Health Organization (December 2009). "Global reductions in measles mortality 2000-2008 and the risk of measles resurgence". *Weekly Epidemiological Record.*: 509–16. hdl:10665/241466. PMID 19960624.
112. "WHO EpiData" (PDF). World Health Organization (WHO). February 2019. Retrieved 27 March 2019.
113. Young, Megan K; Nimmo, Graeme R; Cripps, Allan W; Jones, Mark A (1 April 2014). "Post-exposure passive immunisation for preventing measles". *Cochrane Database of Systematic Reviews* (4): CD010056. doi:10.1002/14651858.cd010056.pub2. hdl:10072/65474. ISSN 1465-1858. PMID 24687262.
114. <https://news.un.org/ru/tags/kor>, <https://news.un.org/ru/story/2019/12/1368571>
115. <https://news.un.org/ru/story/2019/12/1368571>
116. Ołdakowska A, Marczyńska M (2008). "[Measles vaccination in HIV infected children]". *Medycyna Wieku Rozwojowego.* (2 Pt 2): 675–80. PMID 19418943.
117. Hayman DTS. Measles vaccination in an increasingly immunized and developed world. // *Hum Vaccin Immunother.* 2019;15(1):28-33
118. Wong LP, Wong PF, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. // *Hum Vaccin Immunother.* 2020 Jul 2;16(7):1511-1520
119. Wong LP, Wong PF, Megat Hashim MMAA, Han L, Lin Y, Hu Z, Zhao Q, Zimet GD. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. // *Hum Vaccin Immunother.* 2020 Jul 2;16(7):1611-1622
120. Tirkashev O.S., Matnazarova G. S., Bryantseva E. V., Matyakubova F. E., Rabbimova N. T., Mustaeva G. B. Measles at the present stage. *Web of scientist: international scientific research journal volume 3, issue 5 ISSN:2776-0979, May., 2022 (177-185 стр)*





121. Saidov H.Sh., Tirkashev O.S. Study of the effect of measles vaccination on the epidemic process of the disease. Web of scientist: international scientific research journal volume 4, issue 1-Jan., 2023 (560-565 str).
122. Tirkashev O.S., Mustaeva G.B., Bryanseva Y.V., Matnazarova G.S. Изучение клинических и эпидемиологических особенностей кори. Science and education scientific journal volume 4, issue 2 Feb. – 2023 (420-428 str).
123. Bryanseva E.V., Matnazarova G.S., Abdukaharova M.F., Ne'matova N.U., Tirkashev O.S. Measles does not want to lose ground. Journal of advanced zoology. Volume 44, special issue-02 year, 2023, page 711:718 (711-718 str).
124. Bryanseva E.V., Matnazarova G.S., Tirkashev O.S. Korevaya infeksiya v Uzbekistane. Aktualniye problemi meditsini. Sbornik nauchnix statey respublikanskoy nauchno-prakticheskoy konferensii s mejdunarodnim uchastiyem Gomel, 10 noyabrya 2023 goda (136-137 str). ISSN: 2224-6959.
125. Bryanseva E.V., Matnazarova G.S., Shakir N.K., Tirkashev O.S. Vspishka kori v respubliki Uzbekistan i yeyo vaksinatziya. Toshkent tibbiyot akademiyasi. «Yosh olimlar jurnali» №8 (11), 2023 (156-162 str).
126. Tirkashev O.S., Matnazarova G.S., Bryanseva E.V. Qizamiqning klinik va epidemiologik xususiyatlarini o'rganish. Biologiya va tibbiyot muammolari. №2 (143) 2023 (256-260 str)

